Prednicone

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prednicone

What is Prednicone? Identity and Classification

Property Description
Active ingredient Prednisolone Acetate
Form Ophthalmic Suspension, Ophthalmic Ointment
Pharmacological class Glucocorticoid (Synthetic Corticosteroid)
General purpose Suppression of ocular inflammation and swelling
Origin Synthetic

Prednicone is an ophthalmic preparation whose active compound is Prednisolone Acetate, a potent synthetic corticosteroid classified as a Glucocorticoid. This drug is strictly a prescription-only medicine. The active ingredient, Prednisolone Acetate, is the 21-acetate ester of Prednisolone, which is itself a synthetic analog of the naturally occurring steroid hormone Cortisol. Its categorization as a glucocorticoid confirms its primary role in modulating immune and inflammatory responses. This means the medicine is specifically designed to suppress the body's overactive reaction to irritants or injury, a function clinically recognized for its essential role in managing severe, acute ocular inflammation.

Prednisolone Acetate: High-Level Purpose and Mechanism

The primary general purpose of this medication is to rapidly and effectively reduce the physical signs of inflammation, such as swelling and redness, which arise from various ocular irritations or immune responses. Its high-level physiological action is that of a powerful anti-inflammatory agent and immunosuppressive agent. Corticosteroids are essential medicines for controlling severe inflammatory and allergic conditions. This confirms that the drug works by blocking the underlying biological processes that cause inflammation and its associated discomfort. It is typically employed in scenarios where the inflammation requires immediate, localized, and strong control.

Drug Form and Route of Administration

The drug is supplied as a specialized dosage form, primarily a sterile ophthalmic suspension or sometimes an ophthalmic ointment, intended exclusively for topical administration to the ocular surface. This topical route of administration is critical for ensuring a high concentration of the anti-inflammatory agent is delivered precisely to the affected anterior segment of the globe, such as the cornea or conjunctiva. The formulation, often an aqueous vehicle suspension, is a type of eye drop designed for localized, targeted action. The suspension form, distinct from true solutions, relies on the physical dispersion of the solid Prednisolone Acetate particles, which requires thorough shaking before use for consistent delivery of the active agent.

What side effects are possible with Prednicone?

Adverse Reactions and Safety Profile

Prednicone, a corticosteroid, is associated with a wide range of adverse reactions affecting multiple organ systems. The incidence of many effects is linked to the dose and duration of treatment.

Common Adverse Reactions generally include fluid retention, alterations in glucose tolerance and blood pressure, increased appetite, weight gain, and behavioral/mood changes such as insomnia or euphoria.

Serious and Clinically Significant Adverse Reactions

The most serious risks stem from the drug's effects on the immune and endocrine systems. Prednicone can cause adrenocortical insufficiency (HPA axis suppression), which requires a gradual dose reduction (tapering) upon discontinuation to avoid a potentially fatal withdrawal crisis. It significantly increases the risk of new, latent, or exacerbated infections (viral, bacterial, fungal, protozoan), and may mask the signs of infection.

Other serious reactions include peptic ulcer with potential perforation or hemorrhage, osteoporosis (decreased bone density) leading to fractures, and ophthalmic effects such as cataracts and glaucoma (increased intraocular pressure).

Population-Specific Safety Notes

  • Pediatric Patients: Long-term therapy may cause growth retardation and developmental delays, necessitating careful monitoring.
  • Pregnancy: The use of Prednicone during the first trimester may cause fetal harm.
  • Systemic Sclerosis (SSc): Use in SSc patients carries an increased risk of Scleroderma Renal Crisis (SRC), particularly at higher doses.

Safety Restriction: Patients receiving immunosuppressive doses should not receive live or live attenuated vaccines.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Prednisolone Acetate Ophthalmic Suspension documents a low probability of acute systemic toxicity due to its topical route of administration. Regulatory information states that acute overdosage is unlikely to occur and will not ordinarily cause acute problems.


Overdose Presentations and Actions

Classification Official Regulatory Statement
Acute Manifestation Overdosage will not ordinarily cause acute problems.
Required Action (Ingestion) Seek immediate medical attention if the product is accidentally swallowed.
Supportive Measure If accidentally ingested, drink fluids to dilute the product.

Potential Severe Outcomes and Context

While acute topical overdose is deemed low-risk, official labeling describes potential severe outcomes associated with the very frequent or prolonged use of the eye drops, which can lead to excessive systemic absorption. These potential outcomes include rare cases of adrenal suppression and Cushing’s syndrome.

Regulatory documents note that the risk for these systemic effects is a particular concern in infants and children following prolonged, excessive exposure. No specific chemical antidote is known for this overdose scenario.

Therapeutic Uses of Prednicone

What Prednicone Treats: Main Uses and Benefits

Prednicone (Prednisolone Acetate Ophthalmic Suspension) is commonly used to help with acute, steroid-responsive inflammation in the front structures of the eye. This medication is applied across domains where additional symptomatic support is needed for severe symptoms related to inflammatory or irritative states.

It is considered relevant for managing significant inflammation affecting the anterior segment of the globe, including the cornea, conjunctiva, and the internal structures of the anterior chamber. This encompasses conditions such as anterior uveitis (iritis), various forms of keratitis, and severe non-infectious conjunctival inflammation. Furthermore, it is commonly used in clinical settings that involve acute or unstable symptom patterns following specific procedures, such as cataract surgery, or in managing inflammation caused by eye injury.

The medication is used for managing symptom clusters that may become intense or disruptive, and helps address pronounced visible signs like tissue swelling and eye redness. By addressing the inflammation, it offers supportive relief for accompanying subjective discomfort, including severe burning, continuous stinging, and allergic itching. This application supports the patient during difficult episodes by easing distress and contributes to improved comfort.

Quick Fact: Relief for symptoms related to inflammatory or irritative states

Regulatory References

  1. NIH DailyMed

Eligibility and Restrictions for Use

Prednicone (Prednisolone Acetate Ophthalmic Suspension) eligibility is strictly defined by government regulatory labeling, primarily establishing clear limits based on infectious status and pre-existing ocular conditions.

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated in individuals with known or suspected hypersensitivity to any component. Absolute prohibitions apply to patients diagnosed with most viral diseases of the cornea and conjunctiva, including Epithelial Herpes Simplex Keratitis, Vaccinia, or Varicella. Further non-eligibility rules cover patients with mycobacterial or fungal diseases of ocular structures, as well as those with acute untreated purulent ocular infections.

Restricted or Conditional Use

Use of Prednicone requires great caution in patients with pre-existing conditions such as glaucoma or a history of herpes simplex infection. Use is restricted in those with thin corneal or scleral tissue due to the risk of perforation. It also requires caution following cataract surgery as it may delay healing.

Age and Reproductive Status

While use in adult and geriatric patients is documented as acceptable, safety and effectiveness in pediatric patients have not been established for the 1% concentration. For pregnant women (Category C), use is only permitted if the potential benefit justifies the potential risk to the fetus. Nursing mothers must decide whether to discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Prednicone (Prednisolone Acetate Ophthalmic Suspension) primarily based on the risk of increased systemic exposure and local additive effects, rather than numerous systemic drug interactions.


Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substances/Class Official Interaction Outcome
Systemic Exposure Increase Strong CYP3A4 inhibitors (e.g., Ritonavir, Cobicistat-containing products). Co-administration is expected to increase the systemic exposure of prednisolone, raising the potential for systemic corticosteroid effects.
Additive Local Risk Other topical ophthalmic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Co-administration carries an additive pharmacodynamic risk of delayed corneal wound healing.

Administration Requirements and Restrictions

Official labeling contains specific requirements for managing these interactions and ensuring proper administration:

  • Timing Separation Rule: To prevent washout and ensure local efficacy, a mandatory separation of at least five minutes must be observed between the application of Prednicone and any other topical ophthalmic drops or ointments.
  • Exposure Monitoring: Co-treatment with strong CYP3A4 inhibitors should be approached with caution. If the combination is necessary, patients must be monitored for systemic corticosteroid side-effects due to the increased plasma concentration of the active ingredient.
  • Other Interactions: Official regulatory documents do not document specific interactions between Prednicone Ophthalmic Suspension and food, alcohol, or herbal products.

Mechanism of Action

The mechanism of action of Prednicone is derived from its active ingredient, Prednisolone Acetate, a synthetic glucocorticoid. The drug modulates activity within the cell's regulatory systems, affecting inflammatory and immune pathways.

Genomic Control via the Glucocorticoid Receptor

The mechanism begins as the active compound enters the cell and acts as an agonist at the intracellular Glucocorticoid Receptor ( GR). This binding initiates a complex that moves to the nucleus, where it alters the cell's gene expression. This fundamental genomic control activates (transactivation) the synthesis of anti-inflammatory proteins while simultaneously suppressing (transrepression) the transcription of pro-inflammatory mediators.

Inhibition of Cytokine and Eicosanoid Cascades

The change in gene expression leads to the inhibition of crucial signaling cascades. By suppressing transcription factors like NF-kappa B and indirectly inhibiting the PLA2 enzyme (via annexin A1 upregulation), the drug stops the synthesis of major inflammatory mediators. This includes pro-inflammatory cytokines ( IL-1, TNF-alpha) and eicosanoid mediators like prostaglandins and leukotrienes.

Physiological Modulation of Immune Cell Migration

The cumulative molecular effects result in physiological consequences that modulate the biological expression of inflammation. The mechanism decreases the expression of adhesion molecules on blood vessel walls, limiting the ability of immune cells (leukocytes) to leave the bloodstream and infiltrate the affected tissue. This mechanism supports the stabilization of capillary walls, resulting in reduced vascular permeability and fluid extravasation into the tissue space.

Dosage and Administration Information

Administration Route and Preparation

The administration of prednisolone acetate ophthalmic suspension is strictly by topical instillation into the eye, and it is not approved for injection or oral use. Due to its formulation as a suspension, the product must be shaken well before using to ensure that the active ingredient is uniformly dispersed for correct dosing. Proper administration also requires hygienic practice, instructing users to avoid contact between the bottle tip and the eye or any other surface.

Dosing and Frequency

The standard initial application involves administering one to two drops into the affected eye(s). The typical maintenance frequency is two to four times daily. However, for more severe acute conditions, the frequency may be temporarily increased during the initial 24 to 48 hours to control the inflammatory response. If other topical ophthalmic products are used concurrently, they should be administered at least five to ten minutes apart.

Course Duration and Withdrawal

The duration of use is highly variable, potentially lasting from a few days up to several weeks, depending on the condition being managed. A crucial component of the administration protocol is the instruction to not discontinue therapy prematurely. For prolonged use, withdrawal of the medication must be managed by gradually decreasing the frequency of applications (tapering), rather than stopping abruptly. Furthermore, soft contact lenses must be removed prior to instillation and should not be reinserted for at least 15 minutes.

Recent Clinical Evidence

Research evidence / Overview of studies for Prednicone


Evidence for use in Chronic Inflammatory Bowel Disease (CIBD)

Research was studied for Prednicone exploring how symptoms change over time for individuals with Chronic Inflammatory Bowel Disease (CIBD), which is a condition marked by functional limitations and cycles of stability and flare-ups. Studies were conducted during periods of increased symptom activity, and research examined outcomes linked to inflammatory or irritative states and patient-reported outcomes describing perceived discomfort.

Studies report how symptoms evolved in the observed populations, and findings describe patterns related to outcomes related to systemic or functional imbalance observed during the study intervals. Research highlights changes measured during the study period, particularly regarding outcomes capturing phases of heightened symptom activity. These studies contribute to the broader evidence landscape by providing insight into short-term changes in these conditions characterized by fluctuating or episodic manifestations.


Evidence for use in Acute Allergic Reactions

Research has explored Prednicone's use in individuals experiencing conditions associated with acute or disruptive episodes, such as severe allergic reactions. The focus of these studies was on outcomes describing episodic or acute changes and outcomes related to physical discomfort. Studies monitored responses over a short time, focusing on episodes where symptoms become more noticeable.

Studies monitored outcomes reflecting daily functioning or activity level, and research examined the observed responses during the study period. Findings help contextualize how patients reported their experience during periods of temporary physiological imbalance. Studies report how symptoms evolved in the observed populations, specifically during the period of heightened symptom activity.


What is still uncertain about Prednicone

A key limitation is that comparative evidence is lacking in many research scenarios, making it difficult to fully understand how Prednicone compares to other available options. Long-term effects are not fully established, and follow-up durations were limited in most controlled trials. Data for long-term outcomes are not fully established, and evidence quality varies across studies concerning how Prednicone was observed in certain patient groups, such as children and older adults. Research is ongoing to address these evidence gaps and synthesize inconsistent findings.

Key Studies & References Corticosteroid use and complications in a US inflammatory bowel disease cohort

Frequently Asked Questions (FAQ)

Common questions about Prednicone (FAQ)


Q: What is the main difference between Prednicone and other corticosteroid medicines?

Official information describes Prednicone's active ingredient, Prednisolone Acetate, as a type of glucocorticoid. Regulatory texts note that this compound is described as having 3 to 5 times the anti-inflammatory effect relative to hydrocortisone when compared by weight.


Q: Is it normal to feel more energetic or restless when taking Prednicone?

Official documents indicate that common adverse reactions for corticosteroids may include behavioral and mood changes. These changes are described as sometimes manifesting as euphoria or insomnia. The official label acknowledges that the drug may be associated with mood disturbances.


Q: Can Prednicone cause changes in mood or sleep patterns?

Official documents list behavioral and mood changes, as well as disturbances in sleep patterns such as insomnia, as common adverse reactions. The medicine may also be associated with more pronounced behavioral and mood disturbances, including severe depression or mood swings.


Q: Are there any common foods or drinks that should be avoided while on Prednicone?

Official regulatory documents specifically state that there are no documented interactions between the ophthalmic suspension formulation of Prednicone and common foods, alcohol, or most herbal products.


Q: Will Prednicone affect my ability to drive or operate machinery?

Regulatory information advises that adverse reactions may include a temporary visual disturbance or blurring after application. Official information also mentions that temporary problems with glare may occur, which is a factor to consider in situations requiring clear vision.


Q: Can Prednicone be used for skin conditions like eczema or dermatitis?

According to the official product label, Prednicone (Prednisolone Acetate Ophthalmic Suspension) is indicated only for treating steroid-responsive inflammation of the eye's front structures, such as the cornea and conjunctiva. It is not indicated for treating systemic skin conditions.


Q: How long can Prednicone be used before monitoring is recommended?

The duration of use is highly variable, often extending from a few days up to several weeks, depending on the condition being treated. Regulatory guidelines specify that if the product is used for 10 days or longer, or more than 6 weeks, official guidelines note that routine monitoring of intraocular pressure is necessary due to the potential risk of conditions like glaucoma.


Q: Can Prednicone be taken by people with diabetes?

A common adverse reaction associated with this class of medicine is an alteration in glucose tolerance, which means it can increase blood sugar levels. Chronic use may lead to hyperglycemia, and patients with diabetes may require careful monitoring.


Q: What happens if I miss a dose of Prednicone?

Regulatory patient information states that if an application is missed, it should be used as soon as possible. However, if it is close to the time for the next scheduled application, the next dose should be used as planned, avoiding double or extra applications.


Q: How is Prednicone different from hydrocortisone?

The active ingredient, Prednisolone Acetate, is a type of glucocorticoid. Official regulatory documents note that this compound is described as having 3 to 5 times the anti-inflammatory effect relative to hydrocortisone when compared by weight.


Q: Are there any known interactions between Prednicone and herbal supplements?

Official regulatory documents specifically state that there are no documented interactions between the ophthalmic suspension formulation of Prednicone and herbal products.


Q: Can Prednicone be used to treat allergies or hay fever?

The medicine is indicated to treat steroid-responsive ocular inflammation. This includes inflammation and swelling that can arise from certain types of non-infectious eye allergies.


Q: What is the typical duration of a course of Prednicone for a flare-up?

The duration of treatment is highly dependent on the specific eye condition and the severity of inflammation. Official guidelines state that the course of therapy may range from a few days to several weeks.


Q: How does Prednicone interact with vaccines, like the flu shot?

Official warnings state that live or live attenuated vaccines are typically not administered to patients receiving immunosuppressive doses of corticosteroids. Other types of vaccines are not specifically mentioned as restricted.


Q: Can I take other medicines for colds or flu while on Prednicone?

Official labeling documents specific interactions with strong CYP3A4 inhibitors (which can increase drug exposure) and other topical ophthalmic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). However, most other common oral cold or flu medicines are not specifically listed as interacting substances.


Q: Are there any known issues with taking Prednicone before or after surgery?

Official warnings note that the use of steroids after certain surgeries, such as cataract surgery, may potentially delay the healing process.

How should Prednicone be stored and disposed of?

How to Store and Dispose of Prednicone?

The storage and disposal of Prednicone (Prednisolone Acetate Ophthalmic Suspension) must adhere strictly to regulatory conditions to ensure stability.

Storage Conditions

Prednicone must be stored at controlled room temperature, typically 15 C to 30 C (59 F to 86 F). It is mandatory to protect the medication from freezing, excessive heat, and direct light. The bottle must be kept tightly closed and stored upright. To maintain sterility, avoid touching the bottle tip to any surface. The product must be kept out of the sight and reach of children.

Disposal

Discard the bottle 28 days after opening, even if solution remains. Do not use after the expiration date. Regulatory instructions mandate that medicines must not be thrown away in household waste or wastewater; consult a pharmacist or healthcare professional for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prednicone found in:

A-Z Index: